Katherine Tkaczuk is an Oncology physician affiliated with University of Maryland, Baltimore. OpenAlex indexes 99 publications with 4,552 citations (h-index 25); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Sponsor: A&G Pharmaceutical Inc.
- 1380GCC: Prospective Study of GP-88 Blood Test in Healthy Women With Baseline Gail Model Risk Assessment Undergoing Screening for Breast Cancer
Sponsor: University of Maryland, Baltimore
- 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
Sponsor: University of Maryland, Baltimore
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year20256 payments
- Novartis Pharmaceuticals CorporationProgram year20253 payments
- Gilead Sciences, Inc.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
82.6%Aromatase Inhibitor66.7%Letrozole77%Anastrozole16%Exemestane7%Part D<11 patientsKinase inhibitor9.1%Verzenio100%Part D<11 patients+ 1 more class in this area
Nervous system
10.3%Opioid Agonist6.5%Oxycodone Hcl100%Part D<11 patientsBenzodiazepine3.8%Lorazepam100%Part D<11 patientsBlood & clotting
3.8%Factor Xa inhibitor3.8%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Identification of Functional Immune Biomarkers in Breast Cancer Patients
International Journal of Molecular Sciences
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Gloria Reeves, MD
University of Maryland, Baltimore
Karen Kotloff, MD
University of Maryland, Baltimore
Christopher Plowe, MD
University of Maryland, Baltimore
Michael Domanski, MD
University of Maryland, Baltimore
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”